2 January 2021 - Late treatment study
Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan
et al., medRxiv, doi:10.1101/2020.12.28.20248920 (Preprint)
Retrospective 186 hospitalized patients in Pakistan showing unadjusted HCQ mortality RR 1.45, p = 0.07. Confounding by indication is likely.
|
risk of death, 45.0% higher, RR 1.45, p = 0.07, treatment 40 of 94 (42.6%), control 27 of 92 (29.3%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted confounding by indication likely, significant unadjusted confounding possible, unadjusted results with no group details.
Sarfaraz et al., 1/2/2021, retrospective, Pakistan, South Asia, preprint, 7 authors, average treatment delay 7.0 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.